Our findings reveal that SQLE is overexpressed in cisplatin‐resistant tumors and its loss restore tumor sensitivity to cisplatin, implicating SQLE as a promising anticancer therapeutic target for cisplatin‐resistant HNSCC. This evidence concerns the gene SQLE and head and neck squamous cell carcinoma.